

Certificate of Mailing (37 C.F.R. §1.8):

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on this 10th day of May 2004.

PC19148A  
IDS For Appln. No. 10/792,241



Bonnie Acosta

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:  
Eleanor DAGOSTINO et al.

Serial No.: 10/792,241

Filed: March 3, 2004

For: PHOSPHATE/SULFATE ESTER  
COMPOUNDS AND PHARMACEUTICAL  
COMPOSITIONS FOR INHIBITING PROTEIN  
INTERACTING NIMA (PIN1)

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

**UNDER 37 C.F.R. § 1.97(b) or 1.97(c)**

**37 CFR § 1.97(b)**

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

**37 CFR § 1.97(c)**

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

- ☐ Applicant requests that the Examiner consider the following copending applications:

Application Serial No.	Filing Date

- ☐ Copies of these copending applications are enclosed.
- ☒ Applicant hereby requests consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- ☐ This application is a continuation, divisional or continuation-in-part of Serial No. [REDACTED]. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- ☒ This application was filed after June 30, 2003, or entered U.S. national stage under 35 U.S.C. § 371, after June 30, 2003. Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (1276 OG 55).
- ☐ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date: May 10, 2004



Karl Neidert  
Attorney For Applicant  
Registration No. 39,313

Agouron Pharmaceuticals, Inc.  
A Pfizer Company  
Legal Division, Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: 858/622-8060  
Fax: 858/678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/792,241
Filing Date	March 3, 2004
First Named Inventor	Eleanor DAGOSTINO et al.
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	PC19148A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup>			
	AA	5,952,467	09/14/1999	Hunter et al.	
	AB	5,972,697	10/26/1999	Hunter et al.	

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	AC	WO99/12962	03/18/1999	Beth Israel Deaconess Medical Center		
	AD	WO99/63931	12/16/1999	The Salk Institute for Biological Studies		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AE	BAGSHAW, Kenneth D. et al., "Antibody-Directed Enzyme Prodrug Therapy: A Review," <i>Drug Development Research</i> , 1995, 34, 220-230.	
	AF	BERTOLINI, Giorgio et al., "A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug," <i>J. Med. Chem.</i> , 1997, 40, 2011-2016.	
	AG	BODOR, Nicholas, "Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems," <i>Advances in Drug Research</i> , 13, 224-331.	
	AH	BUNGAARD, Hans, "Design of Prodrugs," <i>Elsevier Press</i> , 1985	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/792,241
Filing Date	March 3, 2004
First Named Inventor	Eleanor DAGOSTINO et al.
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	PC19148A

AI	DAVIS, Frances M. et al., "Monoclonal Antibodies to Mitotic Cells", <i>Cell Biology</i> , 1983, 80, 2926-2930.
AJ	DEAR, G.J. et al., "Mass Directed Peak Selection, an Efficient..... Resonance Spectroscopy, <i>Journal of Chromatography B</i> , 2000, 748, 281-293.
AK	HENNIG, Lars et al., "Selective Inactivation of Parvulin-Like Peptidyl-Prolyl cis/trans Isomerases by Juglone," <i>Biochemistry</i> , 1998, 37, 5953-5960.
AL	KOFRON, James L. et al., "Determination of Kinetic Constants for Peptidyl Prolyl.....Assay," <i>American Chemical Society</i> , 1991, 30, 6127-6134.
AM	KROGSGAARD-LARSEN, P ed., "Design and Application of Prodrugs, Drug Design and Development," <i>Harwood Academic Publishers</i> , 1991
AN	LU, Kun Ping et al., "A Human Peptidyl-prolyl Isomerase Essential for Regulation of Mitosis," <i>Nature</i> , 1996, 380, 544-547.
AO	LU, Pei-jung et al., "Function of WW Domains as Phosphoserine- or Phosphothreonine-Binding Modules," <i>Science</i> , 283, 1325-1328.
AP	PROX, Axel et al., "Rapid Structure Elucidation of Drug Metabolites by Use of Stable Isotopes," <i>Xenobiotica</i> , 1973, 3, 2, 103-112.
AQ	RANGANATHAN, Rama et al., "Structural and Functional Analysis of the Mitotic Rotamase Pin1 Suggests Substrate Recognition is Phosphorylation Dependent," <i>Cell</i> , 1997, 89, 875-886.
AR	SHAN, Daxian et al., "Prodrug Strategies Based on Intramolecular Cyclization Reactions," <i>Journal of Pharmaceutical Sciences</i> , 1997, 86, 7, 765-767.
AS	SHEN, Minhui et al., "The Essential Mitotic Peptidyl-Prolyl Isomerase Pin1 Binds and Regulates Mitosis-specific Phosphoproteins," <i>Genes &amp; Development</i> , 1998, 12, 706.
AT	SPRAUL, Manfred, "Liquid Chromatography Coupled with High-field Proton NMR for Profiling Human Urine for Endogenous Compounds and Drug Metabolites," <i>Journal of Pharmaceutical &amp; Biomedical Analysis</i> , 1992, 10, 8, 601-605.
AU	STILL, W. Clark et al., "Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution," <i>J. Org. Chem.</i> , 1978, 43, 14, 2923-2925.
AV	WULF, Gerburg M. et al., "Pin1 is Overexpressed in Breast Cancer and Cooperates with Ras signaling in Increasing the Transcriptional Activity of c-Jun Towards Cyclin D1," <i>EMBO Journal</i> , 2001, 13, 3459-3472.
AW	YAFFE, Michael B. et al., "Sequence-Specific and Phosphorylation-Dependent.....Mechanism," <i>Science</i> , 1997, 278, 1957-1960.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/792,241
Filing Date	March 3, 2004
First Named Inventor	Eleanor DAGOSTINO et al.
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	PC19148A

AX

ZHANG, Yixin et al., Substrate-Based Design of Reversible Pin1 Inhibitors," *Biochemistry*, 2002, 41, 11868-11877.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.